Additionally, an analysis of the Chinese subgroup in the Phoenix study found that the incidence of pneumonia-related adverse reactions increased from 2.1% to 9.7% when comparing the BTK inhibitor ibrutinib combined with R-CHOP to the R-CHOP group (13). This evidence concerns the gene BTK and pneumonia.